TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.73 Million EUR | 55.49% |
| 2022 | -15.13 Million EUR | -4.71% |
| 2021 | -14.45 Million EUR | -38.89% |
| 2020 | -10.4 Million EUR | -1108.48% |
| 2019 | -861 Thousand EUR | 91.98% |
| 2018 | -10.73 Million EUR | -99.33% |
| 2017 | -5.38 Million EUR | 49.89% |
| 2016 | -10.74 Million EUR | 33.26% |
| 2015 | -16.1 Million EUR | -16.7% |
| 2014 | -13.79 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.24 Million EUR | 0.0% |
| 2023 Q4 | -1.53 Million EUR | 0.0% |
| 2023 FY | -6.73 Million EUR | 55.49% |
| 2023 Q1 | -1.82 Million EUR | 61.93% |
| 2023 Q2 | -1.82 Million EUR | 0.0% |
| 2023 Q3 | -1.53 Million EUR | 15.91% |
| 2022 Q3 | -2.4 Million EUR | 76.74% |
| 2022 Q2 | -10.32 Million EUR | -100.0% |
| 2022 FY | -15.13 Million EUR | -4.71% |
| 2022 Q1 | -5.16 Million EUR | 32.86% |
| 2022 Q4 | -4.8 Million EUR | -100.0% |
| 2021 Q3 | -3.84 Million EUR | 43.12% |
| 2021 Q2 | -6.76 Million EUR | -100.0% |
| 2021 FY | -14.45 Million EUR | -38.89% |
| 2021 Q1 | -3.38 Million EUR | 24.58% |
| 2021 Q4 | -7.69 Million EUR | -100.0% |
| 2020 Q3 | -2.24 Million EUR | 62.16% |
| 2020 FY | -10.4 Million EUR | -1108.48% |
| 2020 Q4 | -4.48 Million EUR | -100.0% |
| 2020 Q1 | -2.96 Million EUR | -370.95% |
| 2020 Q2 | -5.92 Million EUR | -100.0% |
| 2019 FY | -861 Thousand EUR | 91.98% |
| 2019 Q4 | 1.09 Million EUR | 100.0% |
| 2019 Q3 | 546.5 Thousand EUR | 127.97% |
| 2019 Q2 | -1.95 Million EUR | -100.0% |
| 2019 Q1 | -977 Thousand EUR | 70.77% |
| 2018 Q3 | -3.34 Million EUR | -65.1% |
| 2018 Q4 | -3.34 Million EUR | 0.0% |
| 2018 Q2 | -2.02 Million EUR | 0.0% |
| 2018 Q1 | -2.02 Million EUR | -28.05% |
| 2018 FY | -10.73 Million EUR | -99.33% |
| 2017 Q3 | -1.58 Million EUR | -42.24% |
| 2017 Q1 | -1.11 Million EUR | 18.78% |
| 2017 Q2 | -1.11 Million EUR | 0.0% |
| 2017 Q4 | -1.58 Million EUR | 0.0% |
| 2017 FY | -5.38 Million EUR | 49.89% |
| 2016 Q1 | -4 Million EUR | 1.96% |
| 2016 FY | -10.74 Million EUR | 33.26% |
| 2016 Q4 | -1.36 Million EUR | 0.0% |
| 2016 Q2 | -4 Million EUR | 0.0% |
| 2016 Q3 | -1.36 Million EUR | 65.83% |
| 2015 Q1 | -3.96 Million EUR | 0.0% |
| 2015 Q3 | -4.08 Million EUR | -3.0% |
| 2015 FY | -16.1 Million EUR | -16.7% |
| 2015 Q4 | -4.08 Million EUR | 0.0% |
| 2015 Q2 | -3.96 Million EUR | 0.0% |
| 2014 FY | -13.79 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -91.472% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 95.441% |
| Adocia SA | -21.16 Million EUR | 68.169% |
| Aelis Farma SA | -5.07 Million EUR | -32.651% |
| Biophytis S.A. | -17.02 Million EUR | 60.437% |
| Advicenne S.A. | -7.03 Million EUR | 4.196% |
| genOway Société anonyme | 1.56 Million EUR | 529.708% |
| IntegraGen SA | -171.39 Thousand EUR | -3830.011% |
| Medesis Pharma S.A. | -3.95 Million EUR | -70.123% |
| Neovacs S.A. | -8.74 Million EUR | 22.959% |
| NFL Biosciences SA | -3.74 Million EUR | -79.844% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 8608.381% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -112.429% |
| Sensorion SA | -22.06 Million EUR | 69.47% |
| Theranexus Société Anonyme | -6.82 Million EUR | 1.347% |
| Valbiotis SA | -7.36 Million EUR | 8.578% |
| TheraVet SA | -1.57 Million EUR | -328.851% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 66.89% |
| argenx SE | -272.91 Million EUR | 97.532% |
| BioSenic S.A. | -28.77 Million EUR | 76.593% |
| Celyad Oncology SA | -8.44 Million EUR | 20.265% |
| DBV Technologies S.A. | -67.26 Million EUR | 89.987% |
| Galapagos NV | 211.69 Million EUR | 103.182% |
| Genfit S.A. | -28.89 Million EUR | 76.687% |
| GeNeuro SA | -14.75 Million EUR | 54.354% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 56.203% |
| Innate Pharma S.A. | -7.57 Million EUR | 11.017% |
| Inventiva S.A. | -110.42 Million EUR | 93.9% |
| MaaT Pharma SA | -19.71 Million EUR | 65.837% |
| MedinCell S.A. | -25.03 Million EUR | 73.097% |
| Nanobiotix S.A. | -39.7 Million EUR | 83.033% |
| Onward Medical N.V. | -36.18 Million EUR | 81.382% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -100.898% |
| OSE Immunotherapeutics SA | -23 Million EUR | 70.717% |
| Oxurion NV | -18.96 Million EUR | 64.489% |
| Pharming Group N.V. | -9.75 Million EUR | 30.959% |
| Poxel S.A. | -35.09 Million EUR | 80.804% |
| GenSight Biologics S.A. | -26.22 Million EUR | 74.31% |
| Transgene SA | -22.32 Million EUR | 69.832% |
| Financière de Tubize SA | 88.15 Million EUR | 107.641% |
| UCB SA | 343 Million EUR | 101.964% |
| Valneva SE | -101.42 Million EUR | 93.359% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 76.233% |